Cue Biopharma Announces Proposed Public Offering GlobeNewswire December 18, 2025 BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced that it is commencing an underwritten […]
December 19, 2025 – Sydney, Australia https://mma.prnewswire.com/media/2849170/PMET_Resources_Inc__Share_issuance_to_VW_Group.jpg PMET Resources Inc. (the “Company” or “PMET”) (TSX: PMET) (ASX: PMT) (OTCQX: PMETF) (FSE: R9GA) is pleased to advise that its largest strategic investor, Volkswagen Finance Luxemburg S.A. (Volkswagen), has accepted an offer by the Company to subscribe for 89,125 fully paid common shares in the Company at
Double-Digit Earnings Growth Driven by Best-Selling Global Publishing Board Authorizes $150 Million Expanded Share Repurchase Authorization as Initial Step to Deploy Proceeds from Successful Sale-Leaseback Transactions Scholastic Corporation (NASDAQ: SCHL), the global children's publishing, education and media company, today reported financial results for the Company's fiscal second quarter ended November30, 2025. https://mma.prnewswire.com/media/344322/SCHOLASTIC_Logo_v1.jpg Peter Warwick, President
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or
(NASDAQ:BEAM), CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 5:15 p.m. PT in San
(Brussels:GLPG),(Euronext Amsterdam:GLPG), GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the systemic lupus erythematosus study, GLPG3667 delivered numerical improvements on several secondary endpoints compared to placebo but did not achieve statistical significance in primary endpoint analysis The
Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus GlobeNewswire December 18, 2025 GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the systemic lupus erythematosus study,
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire December 18, 2025 CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 44th Annual J.P.
Stanley Black & Decker(NYSE: SWK)will broadcast its fourth quarter and full year 2025 earnings webcast on Wednesday, February 4, 2026. The webcast will begin at 8:00AM ET. A news release outlining the financial results will be distributed before the market opens on Wednesday, February 4, 2026. A slide presentation which will accompany the call will
LEIFRAS Co., Ltd. (Nasdaq: LFS) (the “Company” or “Leifras”), a sports and social business company dedicated to youth sports and community engagement,today announced its unaudited financial results for the nine months ended September 30, 2025. Financial Highlights for the NineMonths Ended September30, 2025 — Revenuewas JPY8.6billion ($57.8million) for the nine months ended September 30, 2025,